Androgenic Therapy for Advanced Breast Cancer in Women

Abstract

A randomized clinical trial of calusterone and testolactone according to the protocol of the Cooperative Breast Cancer Group (CBCG) produced objective remissions of advanced breast cancer in 28% of women receiving calusterone and 18% of those given testolactone. Effectiveness of the calusterone has prompted a dose-response study by the CBCG to determine the most effective dose of this androgen for use in treatment of breast cancer.